Page last updated: 2024-11-05

decan-4-olide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

gamma-decalactone : A gamma-lactone that is oxolan-2-one substituted by a hexyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12813
CHEMBL ID365740
CHEBI ID145740
SCHEMBL ID113200
MeSH IDM0284749

Synonyms (99)

Synonym
unii-7hls05kp9o
ec 211-892-8
5-17-09-00093 (beilstein handbook reference)
7hls05kp9o ,
decanoic acid, .gamma.-lactone
.gamma.-n-decalactone
nsc-24248
4-decanolide
4-hexyl-4-butanolide
nsc26510
.gamma.-n-hexyl-.gamma.-butyrolactone
decanolide-1,4
2(3h)-furanone, 5-hexyldihydro-
.gamma.-decanolactone
706-14-9
hydroxydecanoic acid .gamma.-lactone
4-hexyl-.gamma.-butyrolactone
5-hexyltetrahydro-2-furanone
nsc-26510
.gamma.-hexyl-.gamma.-butyrolactone
nsc24248
.gamma.-decalactone
4-hydroxydecanoic acid, .gamma.-lactone
5-hexyldihydro-2(3h)-furanone
decanolactone
wln: t5ovtj e6
2-decalactone
.gamma.-hexylbutyrolactone
4-hexyl-4-hydroxybutanoic acid lactone
decanoic acid, gamma-lactone
4-hydroxydecanoic acid, gamma-lactone
5-hexyldihydrofuran-2(3h)-one
nsc 26510
gamma-decalactone
einecs 211-892-8
gamma-decalactone (natural)
4-hexyl-gamma-butyrolactone
gamma-hexyl-gamma-butyrolactone
gamma-decanolactone
ai3-36026
nsc 24248
hydroxydecanoic acid gamma-lactone
gamma-n-hexyl-gamma-butyrolactone
decanoic acid, 4-hydroxy-, gamma-lactone
gamma-n-decalactone
decan-4-olide
hydroxydecanoic acid, gamma-lactone
fema no. 2360
brn 0117547
gamma-decalactone, >=98%, fcc, fg
gamma-decanolactone, 98%
5-hexyl-dihydro-furan-2-one
bdbm50167997
CHEMBL365740 ,
H0233
CHEBI:145740
5-hexyloxolan-2-one
4-hydroxydecanoic acid gamma-lactone
NCGC00248286-01
NCGC00254995-01
cas-706-14-9
dtxcid002109
tox21_301095
dtxsid4022109 ,
FT-0626610
STL372952
AKOS015905260
S5375
gamma-decalactone [fcc]
decalactone gamma
.gamma.-decalactone [fhfi]
gamma decalactone
gamma-decalactone [inci]
SCHEMBL113200
BBL027521
gamma-n-hexyl-butyrolactone
4-n-hexyl-4-butanolide
gamma-n-hexyl butyrolactone
W-104547
2825-92-5
(.+/-.)-.gamma.-decanolactone
4-decalactone
.gamma.-decanolide
4-hydroxydecanoic acid lactone
decanoic acid, 4-hydroxy-, .gamma.-lactone
mfcd00005404
gamma-decalactone, analytical reference material
D70097
xi-5-hexyldihydro-2(3h)-furanone
J-017021
Q423956
VS-08558
CCG-266362
CS-W017696
HY-N7105
SY015566
STARBLD0003214
??decalactone
gamma -decanolactone

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"We propose that the toxic effects of gamma-decalactone on yeast may be initially linked to a strong interaction of the compound with cell membrane lipids and components."( Mechanisms underlying the toxicity of lactone aroma compounds towards the producing yeast cells.
Aguedo, M; Belin, JM; Beney, L; Waché, Y, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
flavouring agentA food additive that is used to added improve the taste or odour of a food.
food additiveAny substance which is added to food to preserve or enhance its flavour and/or appearance.
anticonvulsantA drug used to prevent seizures or reduce their severity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
gamma-lactoneA lactone having a five-membered lactone ring.
tetrahydrofuranoneAny oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.00180.003041.611522,387.1992AID1159553
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)110.00000.00011.774010.0000AID241334
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (5.17)18.2507
2000's23 (39.66)29.6817
2010's22 (37.93)24.3611
2020's10 (17.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (8.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (91.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]